Article
Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program.
Microbiology spectrum - 4 Nov 2025
Kimbrough John H, Karr Maura H, Nguyen Sean T, DeJonge Boudewijn L M, Longshaw Chris, Takemura Miki, Yamano Yoshinori, Castanheira Mariana, Mendes Rodrigo E
Abstract excerpt
Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR) Pseudomonas aeruginosa by IDSA guidelines. The activity of cefiderocol and the three BL-BLI combinations described above was examined against DTR P. aeruginosa and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.